rabies vaccine
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Rabies Post-exposure Prophylaxis
Conditions
Rabies Post-exposure Prophylaxis
Trial Timeline
Mar 1, 2006 → May 1, 2006
NCT ID
NCT00345319About rabies vaccine
rabies vaccine is a phase 3 stage product being developed by Novartis for Rabies Post-exposure Prophylaxis. The current trial status is completed. This product is registered under clinical trial identifier NCT00345319. Target conditions include Rabies Post-exposure Prophylaxis.
What happened to similar drugs?
2 of 14 similar drugs in Rabies Post-exposure Prophylaxis were approved
Approved (2) Terminated (0) Active (12)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00345319 | Phase 3 | Completed |
Competing Products
20 competing products in Rabies Post-exposure Prophylaxis